• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

教育、生活方式风险因素、治疗选择与多发性硬化症进展

Education, Lifestyle Risk Factors, and Treatment Choices and Multiple Sclerosis Progression.

作者信息

Guo Jie, Olsson Tomas, Hillert Jan, Alfredsson Lars, Hedström Anna Karin

机构信息

Department of Nutrition and Health, China Agricultural University, Beijing, China.

Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.

出版信息

JAMA Netw Open. 2025 Jul 1;8(7):e2520142. doi: 10.1001/jamanetworkopen.2025.20142.

DOI:10.1001/jamanetworkopen.2025.20142
PMID:40643911
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12254889/
Abstract

IMPORTANCE

The implications of socioeconomic factors, including educational level, for multiple sclerosis (MS) progression remain unclear. Understanding whether educational level directly affects MS outcomes or is confounded by lifestyle risk factors and treatment choices could inform personalized care strategies.

OBJECTIVE

To investigate the association between educational level and outcomes related to MS, including worsening of disability, cognition, and health-related quality of life, after adjusting for potential confounding factors or mediation by lifestyle factors and treatment.

DESIGN, SETTING, AND PARTICIPANTS: This cohort study used data from 2 large, population-based case-control studies conducted in Sweden from April 2005 to December 2019 that used Swedish MS Registry data with detailed clinical and sociodemographic information. Patients with relapsing-onset MS aged 25 years or older at disease onset after 1995 were followed up from diagnosis until April 6, 2022, with a mean (SD) follow-up time of 10.4 (5.4) years. Data analysis was performed from July 2024 to November 2024.

EXPOSURE

Educational level categorized as presecondary (9 to 10 years of compulsory school), secondary (2 to 4 years of high school or college), and postsecondary (higher university education) July 2024 to November 2024.

MAIN OUTCOMES AND MEASURES

The primary outcome was confirmed disability worsening defined as a 1-point increase in Expanded Disability Status Scale (EDSS) score sustained across 2 follow-up visits at least 24 weeks apart. Secondary outcomes were worsening of health-related quality of life, measured by the MS Impact Scale (MSIS-29) physical and psychological subscale scores, and cognitive disability worsening, measured by a decrease in Symbol Digit Modalities Test (SDMT) score. Cox proportional hazards regression was used to evaluate associations between educational level and disability progression.

RESULTS

Of 3695 participants with MS, 2656 (71.9%) were female, with a mean (SD) age at diagnosis of 39.1 (9.1) years. Lower educational level was associated with older age at disease onset (mean [SD] age at onset: 42.2 [10.2] years for presecondary educational level vs 36.0 [8.4] years for postsecondary educational level), worse baseline clinical status (mean [SD] EDSS 2.7 [2.0] for presecondary education vs 1.7 [1.5] for postsecondary education), and lower likelihood of receiving second-line therapies (mean [SD] 164 [36.9%] for presecondary education vs 869 [54.1] for postsecondary education). In unadjusted analyses, lower educational level was associated with faster disability progression (ie, worsening), but this association was no longer significant after adjusting for treatment and lifestyle factors (adjusted hazard ratio [AHR], 1.14; 95% CI, 0.97-1.33). No associations were found between educational level and changes in MSIS-29 scores (AHR, 1.14 [95% CI, 0.90-1.44] for the MSIS-29 physical subscale and AHR, 1.00 [95% CI, 0.79-1.26] for the MSIS-29 psychological subscale) or SDMT performance over the 15-year follow-up (AHR, 1.05; 95% CI, 0.76-1.46). Mediation analysis revealed that treatment and lifestyle factors accounted for 79.9% of the observed association between education level and disability progression.

CONCLUSIONS AND RELEVANCE

In this cohort study of participants with MS, observed differences in disability worsening by educational level were largely accounted for by lifestyle and treatment factors, suggesting that educational level itself may not be independently associated with MS progression.

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f730/12254889/b6cc4071edbf/jamanetwopen-e2520142-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f730/12254889/b6cc4071edbf/jamanetwopen-e2520142-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f730/12254889/b6cc4071edbf/jamanetwopen-e2520142-g001.jpg
摘要

重要性

社会经济因素,包括教育水平,对多发性硬化症(MS)进展的影响尚不清楚。了解教育水平是直接影响MS结局,还是被生活方式风险因素和治疗选择所混淆,可为个性化护理策略提供依据。

目的

在调整潜在混杂因素或生活方式因素及治疗的中介作用后,研究教育水平与MS相关结局之间的关联,这些结局包括残疾恶化、认知以及健康相关生活质量。

设计、背景和参与者:这项队列研究使用了2005年4月至2019年12月在瑞典进行的2项大型基于人群的病例对照研究的数据,这些数据来自瑞典MS登记处,包含详细的临床和社会人口学信息。对1995年后发病时年龄在25岁及以上的复发型MS患者从诊断开始进行随访,直至2022年4月6日,平均(标准差)随访时间为10.4(5.4)年。数据分析于2024年7月至2024年11月进行。

暴露因素

教育水平分为小学前(9至10年义务教育)、中学(2至4年高中或大学)和高等教育(高等大学教育)。

主要结局和测量指标

主要结局是确诊的残疾恶化,定义为扩展残疾状态量表(EDSS)评分增加1分,且在至少相隔24周的2次随访中持续存在。次要结局是健康相关生活质量恶化,通过MS影响量表(MSIS-29)身体和心理子量表评分来衡量,以及认知残疾恶化,通过符号数字模态测试(SDMT)评分降低来衡量。采用Cox比例风险回归评估教育水平与残疾进展之间的关联。

结果

在3695名MS参与者中,2656名(71.9%)为女性,诊断时的平均(标准差)年龄为39.1(9.1)岁。较低的教育水平与发病时年龄较大相关(小学前教育水平发病时的平均[标准差]年龄:42.2[10.2]岁,高等教育水平为36.0[8.4]岁),基线临床状态较差(小学前教育的平均[标准差]EDSS为2.7[2.0],高等教育为1.7[1.5]),接受二线治疗的可能性较低(小学前教育的平均[标准差]为164[36.9%],高等教育为869[54.1%])。在未调整的分析中,较低教育水平与更快的残疾进展(即恶化)相关,但在调整治疗和生活方式因素后,这种关联不再显著(调整后的风险比[AHR],1.14;95%置信区间,0.97 - 1.33)。在15年的随访中,未发现教育水平与MSIS-29评分变化(MSIS-29身体子量表的AHR,1.14[95%置信区间,0.90 - 1.44];MSIS-29心理子量表的AHR,1.00[95%置信区间,0.79 - 1.26])或SDMT表现之间存在关联(AHR,1.05;95%置信区间,0.76 - 1.46)。中介分析显示,治疗和生活方式因素占教育水平与残疾进展之间观察到的关联的79.9%。

结论和相关性

在这项针对MS参与者的队列研究中,观察到的教育水平在残疾恶化方面的差异在很大程度上由生活方式和治疗因素所解释,这表明教育水平本身可能与MS进展没有独立关联。

相似文献

1
Education, Lifestyle Risk Factors, and Treatment Choices and Multiple Sclerosis Progression.教育、生活方式风险因素、治疗选择与多发性硬化症进展
JAMA Netw Open. 2025 Jul 1;8(7):e2520142. doi: 10.1001/jamanetworkopen.2025.20142.
2
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.对首次出现提示多发性硬化症临床发作的患者使用疾病修饰药物进行治疗。
Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD012200. doi: 10.1002/14651858.CD012200.pub2.
3
Azathioprine for people with multiple sclerosis.硫唑嘌呤用于多发性硬化症患者。
Cochrane Database Syst Rev. 2024 Dec 9;12(12):CD015005. doi: 10.1002/14651858.CD015005.pub2.
4
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.免疫调节剂和免疫抑制剂治疗复发缓解型多发性硬化症的网状 Meta 分析。
Cochrane Database Syst Rev. 2024 Jan 4;1(1):CD011381. doi: 10.1002/14651858.CD011381.pub3.
5
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
6
Physical activity, diet and other behavioural interventions for improving cognition and school achievement in children and adolescents with obesity or overweight.身体活动、饮食及其他行为干预措施对改善肥胖或超重儿童及青少年认知和学业成绩的作用
Cochrane Database Syst Rev. 2018 Mar 2;3(3):CD009728. doi: 10.1002/14651858.CD009728.pub4.
7
Physical activity, diet and other behavioural interventions for improving cognition and school achievement in children and adolescents with obesity or overweight.身体活动、饮食及其他行为干预对改善肥胖或超重儿童及青少年认知和学业成绩的作用
Cochrane Database Syst Rev. 2018 Jan 29;1(1):CD009728. doi: 10.1002/14651858.CD009728.pub3.
8
Is Kinesiophobia Associated With Quality of Life, Level of Physical Activity, and Function in Older Adults With Knee Osteoarthritis?恐动症与老年膝骨关节炎患者的生活质量、身体活动水平及功能是否相关?
Clin Orthop Relat Res. 2025 Apr 1;483(4):667-676. doi: 10.1097/CORR.0000000000003278. Epub 2024 Oct 9.
9
Vitamin D for the management of multiple sclerosis.维生素D用于多发性硬化症的管理。
Cochrane Database Syst Rev. 2018 Sep 24;9(9):CD008422. doi: 10.1002/14651858.CD008422.pub3.
10
Computer and mobile technology interventions for self-management in chronic obstructive pulmonary disease.用于慢性阻塞性肺疾病自我管理的计算机和移动技术干预措施。
Cochrane Database Syst Rev. 2017 May 23;5(5):CD011425. doi: 10.1002/14651858.CD011425.pub2.

本文引用的文献

1
Obesity Affects Disease Activity and Progression, Cognitive Functioning, and Quality of Life in People With Multiple Sclerosis.肥胖会影响多发性硬化症患者的疾病活动和进展、认知功能以及生活质量。
Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200334. doi: 10.1212/NXI.0000000000200334. Epub 2024 Nov 13.
2
Premorbid Sociodemographic Status and Multiple Sclerosis Outcomes in a Universal Health Care Context.普遍医疗保健背景下的发病前社会人口统计学状况与多发性硬化症结局。
JAMA Netw Open. 2023 Sep 5;6(9):e2334675. doi: 10.1001/jamanetworkopen.2023.34675.
3
Locus for severity implicates CNS resilience in progression of multiple sclerosis.
严重程度的定位提示多发性硬化进展中中枢神经系统的弹性。
Nature. 2023 Jul;619(7969):323-331. doi: 10.1038/s41586-023-06250-x. Epub 2023 Jun 28.
4
Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression.口服烟草与吸烟对多发性硬化症疾病活动和进展的影响。
J Neurol Neurosurg Psychiatry. 2023 Aug;94(8):589-596. doi: 10.1136/jnnp-2022-330848. Epub 2023 Mar 31.
5
Association of obesity with disease outcome in multiple sclerosis.肥胖与多发性硬化疾病结局的关联。
J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):57-61. doi: 10.1136/jnnp-2022-329685. Epub 2022 Nov 1.
6
Interpreting change on the Symbol Digit Modalities Test in people with relapsing multiple sclerosis using the reliable change methodology.使用可靠变化方法解读复发型多发性硬化患者符号数字模态测验的变化。
Mult Scler. 2022 Jun;28(7):1101-1111. doi: 10.1177/13524585211049397. Epub 2021 Oct 6.
7
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility.多发性硬化症基因组图谱提示外周免疫细胞和小胶质细胞与易感性有关。
Science. 2019 Sep 27;365(6460). doi: 10.1126/science.aav7188.
8
Socioeconomic status and disability progression in multiple sclerosis: A multinational study.社会经济地位与多发性硬化症残疾进展:一项多国研究。
Neurology. 2019 Mar 26;92(13):e1497-e1506. doi: 10.1212/WNL.0000000000007190. Epub 2019 Feb 22.
9
Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis.符号数字模态测验:一种用于测量多发性硬化症认知功能的有效临床试验终点指标。
Mult Scler. 2019 Nov;25(13):1781-1790. doi: 10.1177/1352458518808204. Epub 2018 Oct 18.
10
Class II HLA interactions modulate genetic risk for multiple sclerosis.II类人类白细胞抗原相互作用调节多发性硬化症的遗传风险。
Nat Genet. 2015 Oct;47(10):1107-1113. doi: 10.1038/ng.3395. Epub 2015 Sep 7.